Japanese pharmaceuticals company Astellas Pharma Inc., which has a staff of 15,000 worldwide and is headquartered in Tokyo, has sold three of its European production sites in Munich/Germany, Killorglin/Ireland and Carugate/Italy with a total of approximately 400 employees, to companies of the Temmler Group. The complex transaction called for the sale of the sites in Munich and Killorglin by way of an asset deal and the sale of the Carugate site by means of a share deal.
In future Temmler will manufacture products for Astellas at the three sites. To this end the parties concluded long-term supply contracts. Workforce reduction is not planned in connection with the transaction.
For Astellas, the sale marks an important step in its consolidation of sites and optimisation of production. The transaction allows Temmler to develop new lines of business.
Astellas was assisted by the following Gleiss Lutz team:
Dr. Rainer Loges (lead partner, M&A/Corporate, Munich), Dr. Herwig Lux (Pharmaceuticals/IP, Stuttgart), Dr. Burkard Göpfert (Labour Law, partner, Munich), Dr. Stefan Weidert (IT, partner, Berlin), Dr. Christian Steinke (Real Estate, partner, Berlin), Dr. Tobias Falkner (M&A/Corporate, Munich), Dr. Hendrik Maroldt (Real Estate, Berlin) and Dr. Jan C. Balssen (Competition/Antitrust, Munich).
Gleiss Lutz had the lead in the overall transaction. Law firm Matheson Ormsby Prentice advised Astellas in Ireland, and Franzosi Dal Negro Pensato Setti in Italy.
Gleiss Lutz already previously provided its support for the German part of the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. into Astellas Pharma Inc. in 2005, and advised Astellas on subsequent corporate restructuring.
Forward
